According to Regeneron, the drug was under a priority review by the FDA, which is offered when a drug offers major advances in treatment or for a condition that has no adequate therapy. Two phase 3 clinical studies of almost 2,500 patients determined injection every two months after three initial monthly injections maintained or improved visual acuity equivalent to monthly doses of Lucentis.
Related Articles on Ophthalmology:
10 Recent Findings on Ophthalmology
Surgery Devices, Minimally Invasive Procedures to Drive the Ophthalmic Surgery Market
Report: Vision Problems Decline in People With Diabetes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
